Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation. Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Yang, Yuqi, Ji, Ning, Teng, Qiu-Xu, Cai, Chao-Yun, Wang, Jing-Quan, Wu, Zhuo-Xun, Lei, Zi-Ning, Lusvarghi, Sabrina, Ambudkar, Suresh V., Chen, Zhe-Sheng
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236772/
https://ncbi.nlm.nih.gov/pubmed/32477943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00700
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires